29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis

      research-article
      , PhD 1 , , , RPh, MBA 1 , , MBA, MA 2 , , MD, FAAFP 3
      Diabetes Technology & Therapeutics
      Mary Ann Liebert, Inc.
      Diabetes, Continuous glucose monitoring, Adherence, Discontinuation, Cost

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Traditional continuous glucose monitoring (CGM) provides detailed information on glucose patterns and trends to inform daily diabetes management decisions, which is particularly beneficial for patients with a history of hypoglycemia unawareness. However, a high level of patient adherence (≥70%) is required to achieve clinical benefits. The aim of this study was to assess the impact of real-world patient nonadherence and early discontinuation on healthcare resource use.

          Methods: A cost calculator was designed to evaluate monthly healthcare resource waste within the first year of traditional CGM initiation by combining estimates of real-world nonadherence and early discontinuation from the literature with the wholesale acquisition costs of the current technology in the United States (for a commercial payer and for Medicare), or its equivalent in Sweden, Germany, or the Netherlands.

          Results: Based on an early discontinuation rate of 27% and nonadherence rates of 13.9%–31.1% over the 12 months following initiation, the healthcare resource waste associated with nonadherence and early discontinuation was $220,289 and $21,775, respectively, for every 100 patients initiating CGM in the U.S. commercial payer scenario. In the Medicare scenario, the corresponding figures were $72,648 and $5,675, respectively. In both scenarios, nonadherence and early discontinuation accounted for ∼24% of resources being wasted within the first year of CGM initiation. Similar results were observed using the local costs in the other countries analyzed.

          Conclusions: The healthcare resource waste associated with traditional CGM nonadherence and early discontinuation warrants deliberate consideration when selecting suitable patients for this technology.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

          Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. In this 1-year, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes. Patients received recombinant insulin analogues and were supervised by expert clinical teams. The primary end point was the change from the baseline glycated hemoglobin level. At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P<0.001). The proportion of patients who reached the glycated hemoglobin target (<7%) was greater in the pump-therapy group than in the injection-therapy group. The rate of severe hypoglycemia in the pump-therapy group (13.31 cases per 100 person-years) did not differ significantly from that in the injection-therapy group (13.48 per 100 person-years, P=0.58). There was no significant weight gain in either group. In both adults and children with inadequately controlled type 1 diabetes, sensor-augmented pump therapy resulted in significant improvement in glycated hemoglobin levels, as compared with injection therapy. A significantly greater proportion of both adults and children in the pump-therapy group than in the injection-therapy group reached the target glycated hemoglobin level. (Funded by Medtronic and others; ClinicalTrials.gov number, NCT00417989.) 2010 Massachusetts Medical Society
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            6. Glycemic Targets.

            (2017)
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.

                Bookmark

                Author and article information

                Journal
                Diabetes Technol Ther
                Diabetes Technol. Ther
                dia
                Diabetes Technology & Therapeutics
                Mary Ann Liebert, Inc. (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
                1520-9156
                1557-8593
                01 June 2018
                01 June 2018
                01 June 2018
                : 20
                : 6
                : 420-427
                Affiliations
                [ 1 ]Abbott Diabetes Care , Alameda, California.
                [ 2 ]Asclepius Analytics , New York, New York.
                [ 3 ]Kushner Wellness Center , Los Alamitos, California.
                Author notes
                Address correspondence to: Shengsheng Yu, PhD, Abbott Diabetes Care 1420 Harbor Bay Pkwy, Alameda, CA 94502, E-mail: shengsheng.yu@ 123456abbott.com
                Article
                10.1089/dia.2017.0435
                10.1089/dia.2017.0435
                6014049
                29923774
                75c3be65-fdf0-4020-9d60-3f01cbfa2c1d
                © Shengsheng Yu, et al., 2018; Published by Mary Ann Liebert, Inc.

                This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

                History
                Page count
                Figures: 2, Tables: 2, References: 40, Pages: 8
                Categories
                Original Articles

                diabetes,continuous glucose monitoring,adherence,discontinuation,cost

                Comments

                Comment on this article